<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 14 Feb 2021 13:46:17 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>读NEJM，涨知识I晚期肾癌一线CLEAR研究数据亮眼</title><link>https://mp.weixin.qq.com/s/5hK4WpYsdxNiHE9LMLb_4A</link><description></description><content:encoded><![CDATA[读NEJM，涨知识I晚期肾癌一线CLEAR研究数据亮眼]]></content:encoded><pubDate>Sun, 14 Feb 2021 11:48:26 +0800</pubDate></item><item><title>EGFR突变不可切除局部晚期NSCLC的德瓦鲁单抗巩固治疗II</title><link>https://mp.weixin.qq.com/s/6kaKaK9ldyLI6yVIuu3j-A</link><description></description><content:encoded><![CDATA[EGFR突变不可切除局部晚期NSCLC的德瓦鲁单抗巩固治疗II]]></content:encoded><pubDate>Sun, 14 Feb 2021 11:48:26 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评NRG-GI002：帕博利珠单抗+TNT，未显著改善局部进展期直肠癌NAR评分</title><link>https://mp.weixin.qq.com/s/LbKh99JCFvr3QXRgI9Ya9A</link><description></description><content:encoded><![CDATA[【2021 ASCO-GI】林榕波教授点评NRG-GI002：帕博利珠单抗+TNT，未显著改善局部进展期直肠癌NAR评分]]></content:encoded><pubDate>Sun, 14 Feb 2021 11:48:26 +0800</pubDate></item><item><title>看药闻，涨知识｜武田抗巨细胞病毒药物III期研究详细结果</title><link>https://mp.weixin.qq.com/s/QAmuxZxR79aYS2DVQ8GBbg</link><description></description><content:encoded><![CDATA[看药闻，涨知识｜武田抗巨细胞病毒药物III期研究详细结果]]></content:encoded><pubDate>Sat, 13 Feb 2021 11:26:54 +0800</pubDate></item><item><title>特泊替尼（Tepotinib）治疗脑膜转移MET阳性NSCLC</title><link>https://mp.weixin.qq.com/s/Hs3-5Q93-f8r7-gGTBTRBw</link><description></description><content:encoded><![CDATA[特泊替尼（Tepotinib）治疗脑膜转移MET阳性NSCLC]]></content:encoded><pubDate>Sat, 13 Feb 2021 11:26:54 +0800</pubDate></item><item><title>【Cancer】老年乳腺癌保乳术后辅助治疗选择：放疗、激素治疗还是联合治疗？</title><link>https://mp.weixin.qq.com/s/tTPK73sS2vCJG-nXaXVWCA</link><description></description><content:encoded><![CDATA[【Cancer】老年乳腺癌保乳术后辅助治疗选择：放疗、激素治疗还是联合治疗？]]></content:encoded><pubDate>Sat, 13 Feb 2021 11:26:54 +0800</pubDate></item><item><title>看药闻涨知识I武田申请异体干细胞治疗</title><link>https://mp.weixin.qq.com/s/2480ApzmJgjWbOD0d0j8aA</link><description></description><content:encoded><![CDATA[看药闻涨知识I武田申请异体干细胞治疗]]></content:encoded><pubDate>Fri, 12 Feb 2021 13:38:41 +0800</pubDate></item><item><title>A+学院 | 韩悦教授：和而不同——聚焦TTP与VWD诊疗进展</title><link>https://mp.weixin.qq.com/s/nlyxtiOqzxvLs56Dpxt7Dw</link><description></description><content:encoded><![CDATA[A+学院 | 韩悦教授：和而不同——聚焦TTP与VWD诊疗进展]]></content:encoded><pubDate>Fri, 12 Feb 2021 13:38:41 +0800</pubDate></item><item><title>做辅助治疗研究不易，O药报告膀胱癌辅助治疗研究阳性结果</title><link>https://mp.weixin.qq.com/s/TZLX7qJ5GFUM9ri69oILzw</link><description></description><content:encoded><![CDATA[做辅助治疗研究不易，O药报告膀胱癌辅助治疗研究阳性结果]]></content:encoded><pubDate>Thu, 11 Feb 2021 09:58:42 +0800</pubDate></item><item><title>EGFR和HER2突变不可切除局部晚期NSCLC的德瓦鲁单抗巩固治疗</title><link>https://mp.weixin.qq.com/s/gm5m8cvkThAfZY3Lcn97BQ</link><description></description><content:encoded><![CDATA[EGFR和HER2突变不可切除局部晚期NSCLC的德瓦鲁单抗巩固治疗]]></content:encoded><pubDate>Thu, 11 Feb 2021 09:58:42 +0800</pubDate></item><item><title>灵魂5问，搞定晚期乳腺癌OFS应用难点</title><link>https://mp.weixin.qq.com/s/iZD43H-JEiOyplTLQXYOmg</link><description></description><content:encoded><![CDATA[灵魂5问，搞定晚期乳腺癌OFS应用难点]]></content:encoded><pubDate>Wed, 10 Feb 2021 11:13:43 +0800</pubDate></item><item><title>一周“药”闻（2月1-7日）|新获批的抗肿瘤药物们</title><link>https://mp.weixin.qq.com/s/Rapw38RTPSPbClAnUBB_uQ</link><description></description><content:encoded><![CDATA[一周“药”闻（2月1-7日）|新获批的抗肿瘤药物们]]></content:encoded><pubDate>Wed, 10 Feb 2021 11:13:43 +0800</pubDate></item><item><title>公安部:2020年出生并户籍登记的新生儿共1003.5万</title><link>https://mp.weixin.qq.com/s/sNd7hHmliA8fgMVz2YruMw</link><description></description><content:encoded><![CDATA[公安部:2020年出生并户籍登记的新生儿共1003.5万]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>茅台染指后浪 Oh It&#39;s Moutai</title><link>https://mp.weixin.qq.com/s/cEyTDM2zm-8CKZ0zX9OfLA</link><description></description><content:encoded><![CDATA[茅台染指后浪 Oh It's Moutai]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>维布妥昔单抗（BV）日本上市后临床研究结果</title><link>https://mp.weixin.qq.com/s/ilVfA77Ah7HvoNWnjoe6mg</link><description></description><content:encoded><![CDATA[维布妥昔单抗（BV）日本上市后临床研究结果]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>CD30学院 | 邱立华教授——2020ASH好声音 DLBCL最新进展</title><link>https://mp.weixin.qq.com/s/KDejCYXNjDrinYSc-hHzXA</link><description></description><content:encoded><![CDATA[CD30学院 | 邱立华教授——2020ASH好声音 DLBCL最新进展]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>周彩存教授专访:与您一同聚焦EGFR Exon 20ins突变和ALK阳性NSCLC治疗进展</title><link>https://mp.weixin.qq.com/s/AlEA3CDT4c43UyHhBZiSCQ</link><description></description><content:encoded><![CDATA[周彩存教授专访:与您一同聚焦EGFR Exon 20ins突变和ALK阳性NSCLC治疗进展]]></content:encoded><pubDate>Mon, 08 Feb 2021 13:35:39 +0800</pubDate></item><item><title>周期如此短，医学如何做？</title><link>https://mp.weixin.qq.com/s/fRbZsBLwz5jDOtm1w2zMAw</link><description></description><content:encoded><![CDATA[周期如此短，医学如何做？]]></content:encoded><pubDate>Mon, 08 Feb 2021 13:35:39 +0800</pubDate></item><item><title>NEJM:一项基于人群的乳腺癌相关基因研究</title><link>https://mp.weixin.qq.com/s/-dO2Pmi212IB02bx5rwslw</link><description></description><content:encoded><![CDATA[NEJM:一项基于人群的乳腺癌相关基因研究]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:39:16 +0800</pubDate></item><item><title>【JAMA Oncology】肝癌免疫治疗药物汇总及展望</title><link>https://mp.weixin.qq.com/s/7TPtbPJGpgtcLzuCSR_lqw</link><description></description><content:encoded><![CDATA[【JAMA Oncology】肝癌免疫治疗药物汇总及展望]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:39:16 +0800</pubDate></item></channel></rss>